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Abstract
Objective—To identify patient-care practices related to an increased prevalence of hepatitis C
virus (HCV) infection among chronic hemodialysis patients.
Design—Survey
Setting—Chronic hemodialysis facilities in the United States
Participants—An equal probability two-stage cluster sampling was used to select 87 facilities
from all Medicare-approved providers treating 30–150 patients; 53 facilities and 2933/3680
eligible patients agreed to participate.
Methods—Patients were tested for HCV antibody and HCV RNA. Data on patient-care practices
were collected using direct observation.
Results—Overall prevalence of HCV infection was 9.9% (95% confidence interval [CI], 8.2–
11.6); only 2/294 HCV-positive patients were detected solely by HCV RNA. After adjusting for
non-dialysis-related HCV risk factors, patient-care practices independently associated with higher
prevalence of HCV infection included reusing priming receptacles without disinfection (odds ratio
[OR] 2.3; 95% CI, 1.4–3.9), handling blood specimens adjacent to medications and clean supplies
(OR 2.2; 95% CI, 1.3–3.6), and using mobile carts to deliver injectable medications (OR 1.7; 95%
CI, 1.0–2.8). Independently-related facility covariates were ≥10% patient HCV prevalence (OR
3.0; 95% CI, 1.8–5.2), patient-to-staff ratio ≥7-to-1 (OR 2.4; 95% CI, 1.4–4.1), and treatment
duration ≥2 years (OR 2.4; 95% CI, 1.3–4.4).
Conclusions—This study provides the first epidemiologic evidence of associations between
specific patient-care practices and higher HCV infection prevalence among hemodialysis patients.
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Staff should review practices to ensure that hemodialysis-specific infection control practices are
being implemented, especially handling clean and contaminated items in separate areas, reusing
items only if disinfected, and prohibiting mobile medication/clean supply carts within treatment
areas.
Hepatitis C virus (HCV) infection is associated with a high rate of chronic liver disease and
cirrhosis,1 and chronic hemodialysis patients in the United States have a higher prevalence
of this infection than the general adult population.2,3 HCV-infected renal failure patients are
at increased risk for death whether they remain on hemodialysis or undergo kidney
transplantation,4,5 and current HCV therapy is of limited utility in these patients due to lack
of tolerability and suboptimal response rates.6 Therefore, it is of major concern that HCV
infections continue to be transmitted between chronic hemodialysis patients within their
treatment facilities.7–9
To promote patient-care practices that prevent transmission of HCV and other bloodborne
pathogens in chronic hemodialysis facilities, updated recommendations were published by
the Centers for Disease Control and Prevention (CDC) in 2001.10 In addition to Standard
Precautions, the more stringent precautions that had been recommended for all hemodialysis
patients since 1977 were reiterated.11 There is controversy regarding these recommendations
because there were no epidemiological data that demonstrated relationships between HCV
infection and specific patient-care practices in hemodialysis facilities. We conducted this
study to determine the practices and characteristics associated with an increased prevalence
of HCV infection among chronic hemodialysis patients in the United States.
Methods
Study population and data collection
Facilities were selected for participation from a list of Medicare-approved providers using
equal probability two-stage cluster sampling.12 Dialysis facilities eligible for the study were
located within the continental United States, had an outpatient census of 30 to 150 patients
on 31 December 1998, were Medicare-certified for ≥3 years, and located in cities with ≥3
other eligible facilities within a 34-mile radius to facilitate on-site visits. Patient criteria for
eligibility included age ≥18 years and dialysis at the study facility for ≥30 days. All
participants provided written informed consent. Institutional Review Board approval was
obtained from the University of North Carolina at Chapel Hill and the CDC.
From July 2000 to November 2001, trained research staff visited each facility to enroll
patients and interview them about their medical history and risk factors for HCV. A plasma
sample was collected prior to heparin infusion from each enrolled patient and chart reviews
were conducted. Information on the characteristics and practices of each facility was
obtained from interviews with nurse managers and reviews of procedure manuals. Patient-
care practices, disinfection procedures, and handling of clean and contaminated items were
directly observed by research staff for an average of 2–4 hours per center, and recorded on a
standardized form. Multiple observations of key practices were carried out; five separate
observations of those used to connect and disconnect patients from their dialysis machines,
including decontaminating the dialysis stations; three of preparing, distributing and
administering injections and infusions; five of the contents of staffs’ pockets, and 80 of hand
hygiene and glove changes by staff moving between patient stations and between
contaminated and clean areas.
Laboratory testing
Anti-HCV and HCV RNA detection—All plasma specimens were tested for anti-HCV
by enzyme immunoassay (EIA) (ORTHO® HCV Version 3.0 ELISA, Ortho-Clinical
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Diagnostic Systems, Raritan NJ), and repeatedly reactive specimens by a supplemental anti-
HCV strip immunoblot assay (RIBA® HCV 3.0 SIA, Chiron Corporation, Emeryville CA).
RIBA-indeterminate and RIBA-positive samples were tested for HCV RNA using
Amplicor® HCV (Roche Molecular Systems, Branchburg, NJ). EIA-negative and RIBA-
negative specimens were tested for HCV RNA in 16-member mini-pools using the
discriminatory HCV transcription-mediated amplification (dHCV TMA) component of a
combined HIV-1/HCV assay for blood screening (Procleix™, Chiron Corporation) now
FDA approved as HCV Aptima Assay (Gen-Probe Inc., San Diego, CA).13 Reactive pools
were resolved down to the individual member, and single positives confirmed by Amplicor
HCV and nested RT-PCR. HCV-positivity was defined as anti-HCV positive by RIBA or
HCV RNA positive.
Nucleic acid sequencing and genotyping—A 1590 base pair (bp) nucleotide
fragment encompassing part of the 5′ untranslated region (5′ UTR), the core, and envelope
(E1 and part of the E2) regions of the HCV genome was amplified by first round reverse
transcriptase (RT)-PCR from all HCV RNA-positive samples. For genotyping, first round
PCR products were re-amplified and the sequence of each fragment compared with
published sequences using Multiple comparison and Evolution programs (Accelrys GCG,
version 11.1.2-UNIX, Accelrys Software Inc., San Diego, CA).14
Characterization of HCV quasispecies—We cloned and sequenced the HCV
hypervariable region 1 (HVR1), as previously described,15 from all genotyped patients in
three facilities to determine if HCV-infected patients identified by a cross-sectional study
could be linked to one another on the basis of the relatedness of their virus isolates.
Approximately 32 clones were selected from each specimen, their HVR1 sequences aligned,
and the number of viral variants determined. Preliminary pairwise analysis was conducted
using a multiple sequence alignment program and nucleotide distances were calculated using
the model of Kimura 2-parameter distance (Accelrys GCG, version 11.1.2-UNIX).14
Phylogenetic analysis was performed using DNADIST, NEIGHBOR, SEQBOOT and
DRAWTREE programs in the PHYLIP Phylogeny Inference Package (version 3.66, written
by J. Felsenstein, University of Washington, Seattle, WA). Bootstrap analysis was done to
evaluate the reliability of the phylogenetic tree analysis.16
Statistical analysis
All statistics, unless otherwise stated, were adjusted for correlation resulting from the two-
stage cluster sampling design by use of sampling weights derived from the sampling design,
and robust variance estimates and generalized estimating equations generated by SUDAAN
8 (RTI International, Cary NC). Sampling weights were adjusted for facility non-response
and post-sampling changes to the sampling frame. To assess the generalizability of the
results, study facility and patient characteristics were compared to Medicare-approved
chronic hemodialysis facilities operating in the year 2000 with a census of at least 30
patients and chronic hemodialysis patients from the 2001 United States Renal Data System,
respectively.12,17
The potential association between HCV-positivity and patient characteristics unrelated to
their dialysis was evaluated by univariate and multivariate analyses using the entire study
population and a subpopulation of patients considered at risk for hemodialysis-associated
HCV infection (defined below). Patient characteristics with p<0.05 in univariate analysis
were entered into multivariate models. The analysis of the potential association between
HCV-positivity and hemodialysis-related characteristics was restricted to the subpopulation
of patients considered at risk for hemodialysis-associated HCV infection in their respective
study facilities. These patients had spent ≥80% of their hemodialysis career at the study
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facility, were not known to be HCV-positive at the time of dialysis initiation at the study
facility, attended a study facility with at least one HCV-positive patient, and reported no
history of injection drug use (IDU). This subpopulation comprised 70% of the original study
population. Hemodialysis facility-specific and patient care-related characteristics with
p<0.25 in univariate analysis were entered into multivariate models. Each patient-care
practice was assessed in a separate multivariate model in order to minimize the possibility of
having highly correlated practice variables in the same model. Each model was adjusted for
covariates, i.e., other hemodialysis-related characteristics and patient risk factors unrelated
to dialysis that had been identified as significant in their respective univariate analyses.
Crude and adjusted odds ratios with 95% confidence intervals were calculated. Factors with
p<0.05 in the final models were considered significant.
Results
Study population
Of 87 facilities invited to participate, 53 (61%) agreed. The 53 study facilities had an
average weekly patient census of 77.5, and most (83.0%) were free-standing and for-profit.
These characteristics were not significantly different from all Medicare-approved chronic
hemodialysis facilities with a census of at least 30 patients. Of the 4093 hemodialysis
patients attending the 53 study facilities, 3680 (90%) were eligible and 2933 (79.7%)
participated. The age, gender and racial/ethnic characteristics of the study participants
(Table 1) were similar to all hemodialysis patients in the ESRD database.
Prevalence of HCV infection
All 2933 patients were tested for anti-HCV and HCV RNA. HCV-positivity was confirmed
in 294 for an overall prevalence of 9.9% (95% CI, 8.2%–11.6%); 273 (92.9%) of these were
HCV RNA-positive. HCV prevalence ranged from 0 to 29.4% (median 7.8%, 95% CI,
6.1%–11.1%) among individual facilities, and did not differ significantly by geographic
region.
Of the 294 confirmed HCV-positive patients, 292 (99.3%) were detected with anti-HCV. An
additional 51 samples were EIA–positive, but RIBA- and HCV RNA-negative; these were
judged falsely positive for anti-HCV.
Patient risk factors and HCV infection
IDU was reported by 4.3% of all study participants of whom 84.5% were HCV-positive
compared with 6.5% among those who reported never injecting drugs (Table 1). After
excluding participants who reported IDU, risk factors independently associated with an
increased prevalence of HCV infection included age <60 years, non-Hispanic black race/
ethnicity, having completed >8 years of education, and histories of blood transfusion before
1992, kidney transplantation before 1992, ≥25 lifetime heterosexual partners, and attending
≥3 dialysis facilities (Table 1). In the subpopulation of 2056 patients classified as at risk of
hemodialysis-associated HCV infection, older age, non-Hispanic black race/ethnicity, and
history of blood transfusion were also independently associated with an increased
prevalence of HCV infection.
Hemodialysis-related factors and HCV infection
The characteristics and patient-care practices at the study facilities of the patients at risk of
hemodialysis-associated HCV infection were similar to those of the entire study population.
Sixty-four (3.1%) of the 2056 at-risk patients met the criteria for presumed hemodialysis-
associated HCV infection. By univariate analysis, the prevalence of hemodialysis-associated
HCV infection increased with increasing years treated at the study facility, a higher patient-
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to-staff ratio, and increasing proportion of HCV-positive patients treated at the study facility
(Table 2). There was no relationship between HCV prevalence and reuse of dialyzers or type
of facility ownership.
Patient-care practices associated (p<0.25) with increased prevalence of hemodialysis-
associated HCV infection by univariate analysis included using tape from rolls carried in
staff pockets for multiple patients; using mobile medication carts to distribute medications,
inconsistent cleaning of machine monitors between patients; reusing priming receptacles
without decontaminating between patients; and handling blood specimens in or adjacent to
areas used for medications or clean supplies, regardless of the presence or absence of the
“clean” items at the time of observation (Table 3).
By multivariate analysis, these same patient care practices were independently associated
with an increased prevalence of hemodialysis-associated HCV infection except for using
tape from rolls carried in pockets and inconsistent cleaning of monitors (Table 4). The
facility-related covariates that were consistently associated with an increased prevalence of
infection included treatment at the facility for ≥2 years, patient-to-staff ratio ≥7 to 1, and an
HCV patient prevalence ≥10% (Table 4); age <60 years and non-Hispanic black race/
ethnicity were the two significant patient covariates (data not shown).
Relatedness of HCV isolates among patients
Genotype was determined for 255 (97.7%) of the 261 HCV RNA-positive samples; 59.2%
were 1a, 31.4% 1b, 1.6% 2a, 5.5% 2b, 0.9% 2c, 0.9% 3a, and 0.5% 4a. Forty-one facilities
had two or more patients infected with the same HCV sub-genotype; of these, 11 (20.8%)
had at least one pair of patients whose virus isolates shared ≥96% nucleotide identity in the
HCV core-E1 region.
Samples from all genotyped patients in three of the 11 facilities were selected for
quasispecies characterization. The unweighted HCV RNA prevalence in the three facilities
(identified as numbers 22, 23 and 35) was 11.3% (11/97), 10.5% (8/76) and 29.4% (15/51),
respectively. In facility 22, three (1497, 1530, and 1515) of seven 1a-infected patients shared
identical HVR1 quasispecies (bootstrap value 99%); and in facility 23, two (1677 and 1675)
of five 1a-infected patients had 97.8% homology in HVR1 (bootstrap value 89%) (Figure 1).
These patients had received dialysis on the same or adjacent shifts relative to the patients
infected with related isolates.
Among the 1b-infected patients in facilities 22 and 23, the highest degree of HVR1
quasispecies relatedness was 94.2% (bootstrap value 99%), which was found between the
two patients in facility 23. In facility 35, no phylogenetic clustering among quasispecies was
observed from the 1a- or 1b-infected patients (Figure 1). HCV was classified as
hemodialysis-associated in three of these patients.
Discussion
The most important finding of this study was the identification of specific patient-care
practices related to an increased prevalence of hemodialysis-associated HCV infection,
indicating that HCV transmission in these settings can be reduced or prevented by
modifying these practices. Reusing priming receptacles between patients without
decontamination, handling blood specimens in the same or adjacent areas designated for
medications or clean supplies, and using mobile carts within treatment areas to deliver
injectable medications provide opportunities for cross-contamination of blood in settings
where multiple patients require vascular access for prolonged periods. Patients’ tubing can
become contaminated from being draped over priming receptacles that were not disinfected
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after previous patients’ treatments, and entry points of medication vials and intravenous
solutions can be contaminated by used vacutainers and other injection-related supplies when
they are handled in the same or adjacent areas. Unapparent blood contamination of
medication vials and diluents also can occur when injectables are prepared and distributed
from mobile carts in proximity to patient stations.
HCV in plasma remains viable after drying and environmental exposure to room
temperature for at least 16 hours,18 therefore, blood contaminated surfaces and objects can
serve as sources for HCV transmission,19–22 Similar characteristics for hepatitis B virus
were demonstrated >20 years ago,23 although HCV circulates at lower titers and has a
shorter environmental survival time.18
Higher patient prevalences of HCV, lower staff-to-patient ratios, and failure by staff to
change gloves between patients have been shown to be linearly related to increases in
incidence of HCV infection.24 Inadequate staffing may result in less adherence to
appropriate infection control practices thereby increasing the likelihood of blood
contamination of the environment;25 higher patient HCV prevalences may increase the
probability that such blood contamination contains HCV. 26–29 The non-association with
glove changing and hand hygiene in this study may be related to the extremely low
frequency with which both of these activities were routinely performed;30 a median 11.1%
(range, 3%–43%) of the time by staff when they moved between patient stations or from
contaminated to clean areas.
The inherent difficulty in quantifying facility-related factors that increase the risk for
unapparent environmental blood contamination may explain why many outbreak
investigations did not find associations with specific practices but did report multiple
breaches in infection control practices and generally inadequate hygienic standards in the
involved facilities.7,9,31 These circumstances could explain others’ findings of increased risk
of HCV infection associated with receiving dialysis on the same machine following an
HCV-positive patient or on the same shift with HCV-positive patients, and being connected
to the dialysis machine by the same staff member who had connected an HCV-positive
patient.25,27,32,33
Determining the relatedness of virus isolates between HCV-infected hemodialysis patients
in the same facility has been useful for establishing patient-to-patient transmission in studies
of incident infections.27,31 We were able to demonstrate a genetic link between potential
source patients and patients classified with hemodialysis-associated HCV infection in a few
instances; the failure to do so in others is likely related to the cross-sectional nature of the
study. The turnover in chronic hemodialysis patient populations is high, and transmission
may have occurred from an HCV-infected patient who died or transferred before this study
was conducted.
The other major finding of this study was confirmation that HCV antibody assays are
sufficiently sensitive for routine screening of hemodialysis patients in the United States.10,34
Only 0.08% (two) of >2600 anti-HCV negative patients tested positive for HCV RNA.
Higher rates of HCV RNA detection in anti-HCV negative dialysis patients have been
reported by a few studies, and may have represented patients in the early viremic phase of
acute infection before antibody seroconversion.35,36 This pattern also occurs infrequently in
patients with chronic HCV infection as observed in our study, and has been reported even in
immune competent individuals.34,37 Our study also demonstrated the importance of more
specific testing to confirm anti-HCV immunoassay-positive results as 11% of the EIA
positive results were falsely-positive.
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This study had several limitations. The data collection was performed during 2000 and 2001,
the study design was cross-sectional, and it was difficult to distinguish the impact of the
various practices. However, patient-to-patient transmission of HCV infection in
hemodialysis centers has continued during the past decade and the characteristics of the
more recent outbreaks are no different than those that occurred in the past.7,9,25,27 The study
population was representative of the national database; the HCV infection prevalence
consistent with that reported from national surveillance in the same year as the study, and
risk factors conventionally associated with HCV identified. The quality of patient-care
practices at each facility was measured using direct observation, considered the gold
standard since self-reported data often do not correlate with actual practice.38 Given the low
frequencies with which recommended patient-care practices were performed, the Hawthorne
effect (which occurs when individuals change their behavior when they believe someone is
watching them) was probably minimal and if present, biased our results towards the null.
Further, the at-risk population for hemodialysis-associated infection was conservatively
defined which could have resulted in an underestimate of hemodialysis-associated infections
by classifying the source of some HCV-positive patients as not facility-related.
Our study is the first to identify specific patient-care practices associated with higher HCV
prevalence among chronic hemodialysis patients. Other prevalence studies did not collect
such information, relied on facilities’ self-reports regarding the extent to which “sharing” of
medication vials or supplies was carried out, or interpreted “Universal” now called Standard
Precautions as “adequate” practices for chronic hemodialysis facilities.26,28,31,39 Because
exposure to blood and potentially contaminated items can be routinely anticipated in chronic
hemodialysis facilities, recommendations for precautions in these settings include routinely
wearing gloves when caring for patients or touching patients’ equipment; restricting the use
of common supplies, instruments, and medications for multiple patients; and prohibiting the
use of mobile carts within treatment areas to store or distribute medications and clean
supplies.10,40 A staff member should be designated in every facility to review practices to
ensure they are consistent with these recommendations and applied routinely to all patients.
Staffing needs also should be reviewed to ensure they are not a barrier to implementing best
practices. The recommended practices, and the strategies for overcoming barriers to their
implementation, should be included in continuing education of all staff members.
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Table 1
Prevalence of Hepatitis C Virus (HCV) Infection among Chronic Hemodialysis Patients by Patient
Characteristics and Risk Histories.
Characteristic or Lifetime History No. (%) % HCV Positive*
Unadjusted Odds Ratio
(95% Confidence Interval)*
Adjusted Odds Ratio (95%
Confidence Interval)†
All Participants 2,933 (100) 9.9
Age (years)
 <60 1,288 (43.9) 17.0 4.7 (3.2–6.9) 2.0 (1.4–2.8)
 ≥60 1,645 (56.1) 4.2 1.0 1.0
Gender
 Male 1605 (55.1) 11.6 1.6 (1.2–2.2) 0.7 (0.5–1.01)
 Female 1307 (44.9) 7.4 1.0 1.0
Race/Ethnicity
 White, non-Hispanic 1,231 (42.6) 4.7 1.0 1.0
 Black, non-Hispanic 1,264 (43.7) 16.9 4.1 (3.0–5.5) 2.7 (2.1–3.6)
 Hispanic 267 (9.2) 4.7 1.0 (0.5–2.2) 1.0 (0.5–1.9)
 Other, non-Hispanic 131 (4.5) 4.1 0.9 (0.3–2.4) 0.4 (0.1–2.3)
Years on hemodialysis
 ≥2 1634 (55.8) 11.7 1.6 (1.2–2.1) 1.3 (0.9–1.8)
 <2 1297 (44.3) 7.7 1.0 1.0
Number facilities attended
 1 (study facility) 2206 (75.8) 8.4 1.0 1.0
 2 559 (19.2) 13.0 1.6 (1.2–2.2) 0.9 (0.4–1.9)
 ≥3 144 (5.0) 19.7 2.7 (1.4–5.1) 2.3 (1.2–4.4)
Blood transfusion before 1992
 Yes 592 (20.2) 14.4 1.8 (1.4–2.2) 2.3 (1.2–4.4)
 No 2341 (79.8) 8.8 1.0 1.0
Kidney transplant before 1992
 Yes 72 (2.5) 22.2 2.7 (1.2–5.9) 2.7 (1.7–4.2)
 No 2861 (97.6) 9.6 1.0
Injecting drug use
 Yes 125 (4.3) 84.5 Infinite Not applicable
 No 2781 (95.7) 6.5 1.0
Intranasal drug use
 Yes 267 (9.2) 40.1 9.3 (7.1–12.2) 1.6 (0.9–2.5)
 No 2652 (90.9) 6.7 1.0 1.0
Number opposite sex partners
 ≥25 376 (14.5) 23.0 3.5 (2.4–5.2) 1.9 (1.2–2.9)
 <25 2224 (85.5) 7.8 1.0 1.0
*
Univariate analysis adjusted for complex sampling design.
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†
Calculated using multivariate regression, including adjustment for complex sampling design, after excluding participants with a history of
injecting drug use.













Shimokura et al. Page 13
Table 2
Prevalence of Hemodialysis-Associated Hepatitis C Virus (HCV) Infection among Patients by Selected
Characteristics of Their Treatment and Their Study Facilities.
Patients At Risk For Hemodialysis-Associated HCV Infection*
Study Facility Characteristics
No. (%) of Total
Patients No. (%) % HCV Positive†
Unadjusted Odds Ratio (95%
Confidence Interval)†
Total Patients 2933 (100) 2056 (100) 3.1
Years dialyzed at facility
 <1 826 (28.2) 605 (29.5) 1.4 1.0
 1–<2 663 (22.7) 480 (23.4) 2.0 1.4 (0.6–3.4)
 2–<5 996 (34.0) 692 (33.7) 3.9 2.9 (1.3–6.7) ‡
 ≥5 442 (15.1) 275 (13.4) 6.0 4.6 (1.8–11.4) ‡
Received dialysis as inpatient
 Yes 2584 (90.4) 1792 (88.9) 3.3 1.8 (0.6–5.4)§
 No 273 (9.6) 223 (11.1) 1.8 1.0
Dialyzed at other facilities while traveling
 Yes 696 (23.9) 486 (23.7) 2.2 0.7 (0.4–1.2)§
 No 2213 (76.1) 1567 (76.3) 3.4 1.0
Patient census
 30 – 59 616 (21.0) 386 (18.8) 3.4 1.0
 60 – 89 815 (27.8) 588 (28.6) 2.3 0.7 (0.2–2.3)
 90 – 119 784 (26.7) 574 (27.9) 3.2 0.9 (0.4–2.2)
 ≥120 718 (24.5) 508 (24.7) 3.8 1.1 (0.4–3.3)
Patient to staff ratio
 <5 to 1 208 (7.1) 128 (6.2) 1.9 1.0
 5 – 6 to 1 1600 (54.6) 1100 (53.5) 2.7 1.4 (0.5–3.8)
 ≥7 to 1 1125 (38.4) 828 (40.3) 4.2 2.3 (1.1–4.7) §
Prevalence of HCV-positive patients¶
 0 – <5 768 (26.2) 571 (27.8) 1.2 1.0
 5 – <10 738 (25.2) 540 (26.3) 1.1 0.9 (0.4–2.5)
 10 – <15 884 (30.1) 634 (30.8) 5.0 4.4 (1.8–10.5) ‡
 15 – <19 123 (4.2) 60 (2.9) 3.3 2.8 (1.2–6.5) ‡
 ≥>20 420 (14.3) 251 (12.2) 9.2 8.5 (3.6–19.8) ‡
*
Defined as patients who had spent ≥80% of their hemodialysis career at the study facility, were not known to be HCV-positive at the time of
admission to the study facility, attended a study facility with at least one HCV-positive patient, and reported no history of injecting drug use.
†
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¶
Includes all HCV-positive patients treated at the facility regardless of source.
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Table 4
Multivariate Analysis of Patient-Care Practices Associated with Increased Prevalence of Hemodialysis-






Priming receptacles reused between patients without cleaning or disinfection 2.3 (1.4–3.9)
Blood specimens handled in or adjacent to an area where medications were being prepared or other clean supplies
were present
2.2 (1.3–3.8)
Blood specimens handled in or adjacent to a designated clean area, although clean items not present at the time of
observation
2.2 (1.3–3.6)
Mobile medication carts used in treatment areas to distribute injectable medications 1.7 (1.0–2.8)
Dialysis machine monitor knobs decontaminated between patients ≤70% of time 1.2 (0.7–2.1)
Adhesive tape carried in staff pockets 1.5 (0.8–2.9)
Facility-related covariates†
 ≥10% HCV patient prevalence 3.0 (1.8–5.2)
 Patient to staff ratio ≥7 to 1 2.4 (1.4–4.1)
 ≥2 years treatment duration 2.4 (1.3–4.4)
*
For each category, the adjusted odds ratio was calculated relative to the referent group (patients treated in facilities in which the practices were not
observed or which did not have the characteristics) assigned an odds ratio of 1.0.
†
Included in all models, but for purposes of example adjusted odds ratios and 95% confidence intervals shown only from one model. These
measures were similar across all models.
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